Patent ID: 8178570

Claim:
A method of treating a Tie-2 kinase-dependent disease or condition comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to one of the following formulae, wherein E is —S— or —O—, or a pharmaceutically acceptable salt thereof, wherein, R 1 and R 2 , at each occurrence, are independently selected from —H, halogen, —CN, —NH 2 , —CF 3 , —NO 2 , —OR 6 , —N(R 6 )R 7 , —N(R 6 )N(R 6 )R 7 , —S(O) 0-2 R 7 , —SO 2 N(R 6 )R 7 , —CO 2 R 6 , —C(O)N(R 6 )R 7 , —N(R 6 )SO 2 R 7 , —N(R 6 )C(O)R 7 , —N(R 6 )C(O)C 0-6 alkyl-N(R 6 )R 7 , —N(R 6 )CO 2 R 7 , —C(O)R 6 , optionally substituted C 1-6 alkyl, optionally substituted aryl, optionally substituted aryl C 1-6 alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C 1-6 alkyl; L is optionally substituted C 1-4 alkylene; X is —N(R 3 )—; R 3 is selected from —H or optionally substituted alkyl; Z is R 4 C(═O)— or R 4 SO 2 —; R 4 is selected from optionally substituted aryl, optionally substituted aryl C 1-6 alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C 1-6 alkyl; optionally R 3 and R 4 , together with the atoms to which they are attached and any additional atoms that link Z with X, are combined to form a first optionally substituted five- to seven-membered heterocyclyl ring, said first optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P; R 5 is selected from —H, —NO 2 , —NH 2 , —N(R 6 )R 7 , —CN, —OR 6 , and optionally substituted C 1-6 alkyl; Y is independently either ═C(H)— or ═N—, provided that there are no more than three of ═N— in the ring bearing Y; each R 6 is —H or R 7 ; each R 7 is independently selected from optionally substituted C 1-6 alkyl, optionally substituted aryl, optionally substituted aryl C 1-6 alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C 1-6 alkyl; and optionally R 6 and R 7 , when taken together with a common nitrogen to which they are attached, form a second optionally substituted five- to seven-membered heterocyclyl ring, said second optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P.